Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
15°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
G1 Therapeutics Inc
(NQ:
GTHX
)
7.150
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about G1 Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
May 28, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
May 23, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
May 22, 2024
- Jupiter Bioventures will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib for Radioprotection in the US, Europe, Japan, and All Other...
From
G1 Therapeutics
Via
GlobeNewswire
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
May 01, 2024
Via
Benzinga
What's Going On With G1 Therapeutics Stock?
May 09, 2024
According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the report, one offer from TerSera is rumored to have a contingent value right...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
May 09, 2024
Via
Benzinga
GTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 01, 2024
GTHX stock results show that G1 Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
May 01, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
May 01, 2024
- Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding...
From
G1 Therapeutics
Via
GlobeNewswire
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
April 12, 2024
Via
Benzinga
Biotech Innovations Paving the Way in Breast Cancer Fight
April 11, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 28, 2024
Via
Benzinga
Forecasting The Future: 5 Analyst Projections For G1 Therapeutics
February 28, 2024
Via
Benzinga
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
February 28, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Why Is Breast Cancer-Focused G1 Therapeutics Stock Trading Lower Today?
February 13, 2024
Follow G1 Therapeutics as it advances trilaciclib in Phase 3 PRESERVE 2 trial for metastatic triple-negative breast cancer. Updates on trial progress, interim analysis, and potential FDA filing in...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 13, 2024
Via
Benzinga
Evercore ISI Is Warming Up to NextEra Energy (NEE) Stock
February 13, 2024
NextEra Energy stock is on the move Tuesday after Evercore ISI initiated coverage of NEE shares with a bull rating and price target.
Via
InvestorPlace
UBS Just Upped Its Nvidia (NVDA) Stock Price Target
February 13, 2024
Nvidia stock is a hot topic among NVDA traders on Tuesday after the company's shares got a new $850 price target from UBS analysts.
Via
InvestorPlace
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 13, 2024
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance.
Via
Benzinga
Why ZoomInfo Technologies Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
February 13, 2024
Shares of ZoomInfo Technologies Inc. (NASDAQ: ZI) rose sharply in today’s pre-market trading as the company reported stronger-than-expected fourth-quarter financial results.
Via
Benzinga
Why Is Polished.com (POL) Stock Down 33% Today?
February 13, 2024
Polished.com stock is sliding lower on Tuesday as investors in POL react to the company missing a debt payment and other dangers.
Via
InvestorPlace
Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?
February 13, 2024
G1 Therapeutics stock is down on Tuesday after the company provided GTHX investors with an update on a Phase 3 clinical trial.
Via
InvestorPlace
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
February 13, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 13, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
February 13, 2024
Pre-market stock movers are a hot topic on Tuesday and we're diving into all of the biggest winners and losers this morning!
Via
InvestorPlace
Arista Networks Reports Q4 Results, Joins Teradata, Lattice Semiconductor And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
February 13, 2024
U.S. stock futures were lower this morning, with the Nasdaq futures trading lower by around 100 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
February 12, 2024
Via
Benzinga
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
February 12, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
G1 Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.